Mylan NV

$ 19.17 -0.48 (-2.44%)
On watch
Volume: 7,280,292 Avg Vol (1m): 7,360,565
Market Cap $: 9.88 Bil Enterprise Value $: 23.29 Bil
P/E (TTM): 41.69 P/B: 0.83
Earnings Power Value 3.58
Net Current Asset Value -26.7
Tangible Book -20.72
Projected FCF 37.31
Median P/S Value 36.82
Graham Number 0
Peter Lynch Value 3.56
DCF (FCF Based) 19.81
DCF (Earnings Based) 4.92
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.02
Cash-To-Debt ranked lower than
98.25% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
MYL: 0.02
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 2.45, Max: 44.56
Current: 0.02
0.02
44.56
Equity-to-Asset 0.37
Equity-to-Asset ranked lower than
81.73% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
MYL: 0.37
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.19, Med: 0.78, Max: 0.94
Current: 0.37
0.19
0.94
Debt-to-Equity 1.16
Debt-to-Equity ranked lower than
87.92% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
MYL: 1.16
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.01, Med: 0.07, Max: 2.73
Current: 1.16
0.01
2.73
Debt-to-EBITDA 4.86
Debt-to-EBITDA ranked lower than
77.98% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
MYL: 4.86
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 3.19, Med: 4.61, Max: 7.37
Current: 4.86
3.19
7.37
Interest Coverage 1.31
Interest Coverage ranked lower than
91.20% of 648 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
MYL: 1.31
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1.31, Med: 3.08, Max: 4.02
Current: 1.31
1.31
4.02
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.07
DISTRESS
GREY
SAFE
Beneish M-Score -2.69
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 3.74%
WACC 6.63%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 6.30
Operating Margin ranked higher than
52.68% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
MYL: 6.3
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 6.3, Med: 15.14, Max: 17.19
Current: 6.3
6.3
17.19
Net Margin % 2.14
Net Margin ranked lower than
55.61% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
MYL: 2.14
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 2.14, Med: 7.55, Max: 12.04
Current: 2.14
2.14
12.04
ROE % 1.95
ROE ranked lower than
57.09% of 832 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
MYL: 1.95
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 1.95, Med: 9.83, Max: 29.99
Current: 1.95
1.95
29.99
ROA % 0.72
ROA ranked lower than
57.86% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
MYL: 0.72
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 0.72, Med: 3.77, Max: 5.97
Current: 0.72
0.72
5.97
ROC (Joel Greenblatt) % 17.54
ROC (Joel Greenblatt) ranked higher than
68.07% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
MYL: 17.54
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 15.13, Med: 28.81, Max: 38.2
Current: 17.54
15.13
38.2
3-Year Total Revenue Growth Rate 6.60
3-Year Revenue Growth Rate ranked lower than
53.70% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
MYL: 5.3
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -6.1, Med: 15.2, Max: 54.5
Current: 5.3
-6.1
54.5
3-Year Total EBITDA Growth Rate 8.90
3-Year EBITDA Growth Rate ranked higher than
52.56% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
MYL: 7.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -8.3, Med: 11.2, Max: 74.7
Current: 7.5
-8.3
74.7
3-Year EPS w/o NRI Growth Rate -26.30
3-Year EPS w/o NRI Growth Rate ranked lower than
82.96% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
MYL: -26.3
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» MYL's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MYL

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare SZSE:000538 NSE:SUNPHARMA NYSE:ELAN TSE:4523 XTAE:TEVA TSX:WEED SZSE:300122 SHSE:600196 TSE:4507 XPAR:IPN SHSE:600332 TSX:ACB HKSE:03320 TSE:4506 XSWX:VIFN OCSE:LUN TSX:BHC SHSE:600518 TSE:4581 SZSE:000963
Traded in other countries 6MY.Germany MYL1.Switzerland 0R5P.UK
Address Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, GBR, AL10 9UL
Mylan is one of the world's largest generic pharmaceutical manufacturers with operations in the United States, Europe, Asia, Middle East, Africa, and Australia. Generic drug sales constitute approximately 90% of revenue. Remaining sales come from a handful of branded products, primarily epinephrine injector EpiPen. Mylan also owns Matrix, an Indian active pharmaceutical ingredient manufacturer.

Ratios

Current vs industry vs history
PE Ratio (TTM) 41.69
PE Ratio ranked lower than
76.12% of 557 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
MYL: 41.69
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 15.98, Med: 29.14, Max: 112.56
Current: 41.69
15.98
112.56
Forward PE Ratio 4.55
Forward P/E ranked higher than
95.50% of 111 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
MYL: 4.55
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 41.69
PE without NRI ranked lower than
75.54% of 556 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
MYL: 41.69
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 15.98, Med: 29.14, Max: 112.56
Current: 41.69
15.98
112.56
Price-to-Owner-Earnings 14.37
Price-to-Owner-Earnings ranked higher than
67.90% of 324 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
MYL: 14.37
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 10.91, Med: 27.35, Max: 310
Current: 14.37
10.91
310
PB Ratio 0.83
PB Ratio ranked higher than
73.50% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
MYL: 0.83
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.64, Med: 2.14, Max: 7.02
Current: 0.83
0.64
7.02
PS Ratio 0.88
PS Ratio ranked higher than
70.58% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
MYL: 0.88
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.4, Med: 1.69, Max: 3.94
Current: 0.88
0.4
3.94
Price-to-Free-Cash-Flow 12.55
Price-to-Free-Cash-Flow ranked higher than
73.15% of 298 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
MYL: 12.55
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.82, Med: 19.4, Max: 115.12
Current: 12.55
8.82
115.12
Price-to-Operating-Cash-Flow 5.87
Price-to-Operating-Cash-Flow ranked higher than
87.24% of 392 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
MYL: 5.87
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.81, Med: 11.28, Max: 40.9
Current: 5.87
5.81
40.9
EV-to-EBIT 32.58
EV-to-EBIT ranked lower than
77.10% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
MYL: 32.58
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -11.8, Med: 22.7, Max: 74.2
Current: 32.58
-11.8
74.2
EV-to-EBITDA 8.25
EV-to-EBITDA ranked higher than
70.52% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
MYL: 8.25
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -22.6, Med: 11.3, Max: 23.3
Current: 8.25
-22.6
23.3
EV-to-Revenue 2.07
EV-to-Revenue ranked higher than
55.72% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
MYL: 2.07
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 2.7, Max: 5.6
Current: 2.07
1.5
5.6
PEG Ratio 6.01
PEG Ratio ranked lower than
83.60% of 317 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
MYL: 6.01
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.72, Med: 3.27, Max: 13.61
Current: 6.01
0.72
13.61
Shiller PE Ratio 14.84
Shiller PE Ratio ranked higher than
55.95% of 252 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1460.4, Med: 32.75, Min: 0.08
MYL: 14.84
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 14.69, Med: 84.44, Max: 173.66
Current: 14.84
14.69
173.66
Current Ratio 1.51
Current Ratio ranked lower than
76.73% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
MYL: 1.51
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.83, Med: 4.48, Max: 11.71
Current: 1.51
0.83
11.71
Quick Ratio 0.85
Quick Ratio ranked lower than
83.27% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
MYL: 0.85
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.55, Med: 3.24, Max: 8.47
Current: 0.85
0.55
8.47
Days Inventory 128.36
Days Inventory ranked lower than
55.63% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
MYL: 128.36
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 125.79, Med: 132.36, Max: 150.11
Current: 128.36
125.79
150.11
Days Sales Outstanding 76.84
Days Sales Outstanding ranked lower than
56.36% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
MYL: 76.84
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 76.84, Med: 91.36, Max: 107.26
Current: 76.84
76.84
107.26
Days Payable 44.60
Days Payable ranked lower than
56.73% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
MYL: 44.6
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 44.6, Med: 63.21, Max: 101.21
Current: 44.6
44.6
101.21

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.70
3-Year Share Buyback Rate ranked lower than
67.78% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
MYL: -1.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -25.8, Med: -1.7, Max: 7.4
Current: -1.7
-25.8
7.4

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.51
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
82.89% of 374 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 209, Med: 2.11, Min: 0.05
MYL: 0.51
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.51, Med: 1.53, Max: 5.33
Current: 0.51
0.51
5.33
Price-to-DCF (Earnings Based) 3.90
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
91.82% of 110 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
MYL: 3.9
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 0.46, Med: 1.8, Max: 7.86
Current: 3.9
0.46
7.86
Price-to-Median-PS-Value 0.52
Price-to-Median-PS-Value ranked lower than
52.36% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
MYL: 0.52
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.39, Med: 2.27, Max: 8.45
Current: 0.52
0.39
8.45
Price-to-Peter-Lynch-Fair-Value 5.38
Price-to-Peter-Lynch-Fair-Value ranked lower than
93.87% of 212 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
MYL: 5.38
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.67, Med: 1.91, Max: 12.34
Current: 5.38
0.67
12.34
Earnings Yield (Joel Greenblatt) % 3.07
Earnings Yield (Greenblatt) ranked lower than
50.87% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
MYL: 3.07
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -15.9, Med: 4.3, Max: 12.2
Current: 3.07
-15.9
12.2
Forward Rate of Return (Yacktman) % 17.08
Forward Rate of Return ranked higher than
59.38% of 421 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
MYL: 17.08
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 2.7, Med: 13.1, Max: 25
Current: 17.08
2.7
25

More Statistics

Revenue (TTM) (Mil) $ 11,244.9
EPS (TTM) $ 0.46
Beta 1.59
Volatility % 32.84
52-Week Range $ 18.93 - 42.5
Shares Outstanding (Mil) 515.44

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N